PatientView PRESS RELEASE: What Italian Patient Groups Say About Pharma, 2016
No Images? Click here
The Corporate Reputation of Pharma Companies, 2016: from the Perspective of 75 Italian Patient Groups
(3rd edition)
- Published Friday, 11th August 2017
- Part of a series of reports offered by PatientView
- Format is PDF (101 pages)
- These results are derived from a global review of pharma’s corporate reputation (conducted November 2016 to early-February 2017).
- These results are based on the opinions of 75 Italian patient groups (17 specialised in cancer; 10 in diabetes; 6 in HIV/AIDS; and other specialties).
- 16 pharma companies are included in this 2016 Italian analysis: • AbbVie • AstraZeneca • Bayer • Boehringer Ingelheim • Bristol-Myers Squibb • Eli Lilly (Lilly) • GSK • Janssen (Pharmaceutical companies of Johnson & Johnson) • Menarini • Merck & Co • Novartis • Pfizer • Roche • Sandoz • Sanofi and • Teva. The 16 companies were chosen because a minimum of 19 Italian patient groups declared familiarity with each one.
- In response to a survey of pharmaceutical companies, Eisai provided information on its patient centricity and its relations with patient-advocacy groups during 2016-2017 in Italy.
THE QUESTIONNAIRE
Industry-wide questions:
- How the pharma industry’s corporate reputation compares with that of other healthcare industries.
- How the pharma industry’s corporate reputation has changed over the past five years.
- How good or bad the pharma industry is at various activities of relevance to patients and patient groups.
7 indicators show the corporate reputation of individual pharma companies:
- Patient centricity.
- Information for patients.
- Patient safety.
- Usefulness of products.
- Transparency.
- Integrity.
- Patient-group relationships (new for 2016).
INDUSTRY-WIDE FINDINGS
- In 2016, 45.7% of Italian patient groups thought that the pharma industry had an “Excellent” or “Good” corporate reputation (38% of patient groups worldwide thought the same). Despite the higher rating for pharma from Italian patient groups in 2016, the figure is one of the lowest recorded among Italian patient groups since 2012 (the equivalent figure from Italian patient groups in 2015 was 61.9%).
- Italian patient groups in 2016 were also more negative (when compared with the results attained from 19 other countries/ regions of the world) about the pharma industry’s ability to carry out a number of activities regarded as important by patients—most notably, the industry's provision of high-quality patient information. Moreover, only 10% of Italian patient groups thought pharma “Excellent” or “Good” at fair pricing in 2016 [for both, see the two charts, below].
% of respondent patient groups in 2016 from 20 different countries/regions describing pharma as “Excellent” or “Good” at providing high-quality, useful, patient information
% of respondent patient groups in 2016 from 20 different countries/regions describing pharma as “Excellent” or “Good” at having fair pricing policies
PHARMA COMPANIES and ITALIAN PATIENT GROUPS
The number/percentage of patient groups claiming familiarity with individual pharma companies gives an idea of each company’s corporate brand awareness within the patient community in 2016.
- 63 of 2016’s 75 respondent Italian patient groups claimed familiarity with Novartis—making the company the most well known among the respondent Italian patient groups.
Levels of familiarity among Italian patient groups with the 16 featured pharma companies, 2016. Number of respondent Italian patient groups saying that they were familiar with the company
INDIVIDUAL COMPANY FINDINGS—ITALY
- Roche ranked overall 1st for corporate reputation in 2016 among Italian patient groups familiar with it. Roche also ranked 1st for three of the seven indicators of corporate reputation measured in this analysis: the provision of high-quality patient information; patient safety; and transparency. In addition, the company worked with a large number of the respondent Italian patient groups.
- AbbVie ranked overall 2nd for corporate reputation in 2016 among Italian patient groups familiar with it, as well as 1st for three of the seven indicators of corporate reputation: patient centricity; the provision of high-quality, useful, products; and the quality of relationships with patient groups.
- Eli Lilly ranked overall 3rd in Italy in 2016 for corporate reputation, and 1st for the corporate-reputation indicator of integrity.
HIGHS and LOWS—ITALY
Pharma companies’ overall rankings—in PCRIs—among Italian patient groups familiar with each company, 2016 v. 2015: ordered according to the difference between the PCRI values for the two years (high to low)
The Patient Corporate Reputation Index (PCRI) standardises PatientView’s ranking data, to take into account the different numbers of companies included in country/therapy analyses. The ranking is from 0 to 1, with 1 as the best (the highest) rank.
If the Italian corporate-reputation results for 2016 (16 pharma companies analysed) are compared with those of 2015 (11 pharma companies analysed) using a standardised index—the Patient Corporate Reputation Index (PCRI)—findings show that the biggest jump up the Italian rankings, 2015-2016, was for:
- Sandoz—which outperformed in 2016 its respective rankings among Italian patient groups in 2015.
CONTENTS, TABLES and CHARTS—ITALY
Contents
Executive summary.
Italian patient-group relationships with pharma.
Industry-wide findings from Italian patient groups.
Italian patient groups on improving pharma's corporate reputation.
Rankings of the 16 pharma companies among Italian patient groups FAMILIAR with them.
Positioning of the 16 pharma companies among Italian patient groups with which the companies PARTNER.
Profiles of the 16 pharma companies.
- Appendices:
- Comments from respondent Italian patient groups.
- Profile of the 75 respondent Italian patient groups.
- Case study on what pharma companies were doing in patient centricity in Italy, 2016-2017: Eisai Italy.
Company profiles:
Number of Italian patient groups saying that they had a working relationship with the company, 2016.
Company’s average score for the seven indicators of corporate reputation among Italian patient groups familiar with the company, 2016 v. 2015.
Company’s performance at 2015’s six indicators of corporate reputation among Italian patient groups familiar with the company, 2015.
Company’s scores among Italian patient groups familiar with the company, and which worked with the company, for each of the seven indicators of corporate reputation, 2016.
Company’s overall rankings for corporate reputation among patient groups familiar with the company: Italy v. worldwide. Company’s positioning for corporate reputation among patient groups which worked with the company: Italy v. worldwide. All 2016.
Company’s best corporate-reputation indicators among Italian patient groups familiar with the company, 2016.
Company’s Patient Corporate Reputation Index (PCRI): Italian patient groups, 2016 v. 2015.
Company’s rankings among patient groups for the seven indicators of corporate reputation, 2016: Italy v. worldwide; familiar with v. worked with.
Percentage of the Italian patient groups that worked with the company—but which also worked with other companies, 2016.
Performance of the company at corporate reputation among Italian patient groups of different therapy areas, compared with its own Italy-wide average, 2016.
For more information about this Italy analysis, please use contact details below.
